Treatment of chronic HCV infection in special populations.

International Journal of Medical Sciences
John Hoefs, Vikramjit S Aulakh

Abstract

The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the initial treatment. However, populations have been defined that respond less well to routine treatment including African Americans, immune suppressed populations, obese patients and cirrhotic patients. These types of patients are enriched in groups of patients who are non-responders to treatment. This article discusses viral kinetics that may impact treatment response, strategies to maximize treatment effectiveness in these populations and the treatment of non-responders in general. Early viral kinetics can be used to define response or non-response and these results can be used to modify subsequent treatment length and dose.

References

Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·I BicaD R Snydman
Jun 26, 2001·Alimentary Pharmacology & Therapeutics·V Di MarcoA Craxì
Jul 20, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C S GrahamM J Koziel
Aug 2, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K L LindsayUNKNOWN Hepatitis Interventional Therapy Group
Mar 18, 2004·Drugs·Winston Lee, Douglas Dieterich
Jun 9, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lennox J JeffersK Rajender Reddy
Jul 30, 2004·The New England Journal of Medicine·Francesca J TorrianiUNKNOWN APRICOT Study Group
Jul 19, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Gregory T EversonCatherine Ray
Aug 19, 2005·Nature·Francis V Chisari
Aug 19, 2005·Nature·David G Bowen, Christopher M Walker

❮ Previous
Next ❯

Citations

Jan 1, 2011·Therapeutic Advances in Chronic Disease·Emilio Palumbo
Apr 18, 2008·Current Gastroenterology Reports·Emmanuel Thomas, Michael W Fried
Dec 6, 2011·Digestive Diseases and Sciences·John Carl HoefsBernard Joseph Ilagan
Jul 25, 2009·Clinics in Liver Disease·Philippe A Gallay
Aug 30, 2008·The Mount Sinai Journal of Medicine, New York·Poonam Mishra, Donald M Jensen
Dec 1, 2007·Nature Reviews. Drug Discovery·Michael P MannsMichael Houghton
May 13, 2009·American Journal of Therapeutics·Emilio Palumbo
Sep 8, 2015·Current Gastroenterology Reports·Paul Y Kwo, Maaz B Badshah

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology
Jagdish S NachnaniLaura M Alba
Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Michael R CharltonStephen A Harrison
© 2022 Meta ULC. All rights reserved